Palazestrant (OP-1250) is currently in development as a treatment for ER-positive, HER2-negative metastatic breast cancer (ER+/HER2- MBC), in both monotherapy and combination settings. Learn more about our Phase 3 trial, OPERA-01, investigating palazestrant compared to a common therapy.
Palazestrant in the clinic.
Our lead investigational drug, palazestrant (OP-1250), is a novel oral compound developed to completely antagonize the estrogen receptor (ER) and block the ER-mediated cancer cell growth and proliferation signal.
Our pipeline
Indication
- Discovery
- Non-Clinical
- Phase 1
- Phase 2
- Phase 3
- Registration
Palazestrant (OP-1250) - ER+/HER2- Metastatic Breast Cancer
1st line combo with CDK 4/6i ribociclib
In Planning
In Planning
phase 3
2/3 line monotherapy
phase 3
Combo therapy with CDK4/6i ribociclib
In Collaboration with
In Collaboration with
phase 2
Combo therapy with CDK4/6i palbociclib
In Collaboration with
In Collaboration with
phase 2
Combo therapy with PI3Ki alpelisib with PIK3CA mutated
In Collaboration with
In Collaboration with
phase 1
Combo therapy with mTOR inhibitor everolimus
phase 1
OP-3136 KAT6 Inhibitor - Oncology
ER+/HER2+ metastatic breast cancer/castrate-resistant prostate/lung cancer
nonclinical